Chemotherapy for intracranial ependymoma in adults

[1]  Gary D Bader,et al.  Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. , 2015, Cancer cell.

[2]  T. Mikkelsen,et al.  Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. , 2015, Neuro-oncology.

[3]  K. Aldape,et al.  C11orf95–RELA fusion present in a primary supratentorial ependymoma and recurrent sarcoma , 2015, Brain Tumor Pathology.

[4]  A. Parsa,et al.  Prognosis by tumor location in adults with intracranial ependymomas , 2014, Journal of Clinical Neuroscience.

[5]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[6]  V. Zagonel,et al.  Cisplatin and Temozolomide Combination in the Treatment of Supratentorial Anaplastic Ependymoma , 2013, Chemotherapy.

[7]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. , 2013, Neuro-oncology.

[8]  S. Pfister,et al.  Molecular approaches to ependymoma: the next step(s). , 2012, Current opinion in neurology.

[9]  F. Lohr,et al.  Response to temozolomide in supratentorial multifocal recurrence of malignant ependymoma. , 2011, Anticancer research.

[10]  M. Gilbert,et al.  Ependymomas in Adults , 2010, Current neurology and neuroscience reports.

[11]  G. Reifenberger,et al.  MGMT promoter methylation in malignant gliomas: ready for personalized medicine? , 2010, Nature Reviews Neurology.

[12]  R. Fimmers,et al.  Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma Patients , 2009, Clinical Cancer Research.

[13]  M. Chamberlain,et al.  Temozolomide for recurrent intracranial supratentorial platinum‐refractory ependymoma , 2009, Cancer.

[14]  R. Stupp,et al.  Bevacizumab for recurrent ependymoma , 2009, Neurology.

[15]  T. Merchant,et al.  Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. , 2009, The Lancet. Oncology.

[16]  O. Chinot,et al.  Supratentorial ependymomas: Prognostic factors and outcome analysis in a retrospective series of 46 adult patients , 2008, Cancer.

[17]  M. Paglierani,et al.  O6- Methylguanine-DNA-Methyltransferase in Recurring Anaplastic Ependymomas: PCR and Immunohistochemistry , 2008, Journal of chemotherapy.

[18]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[19]  D. Louis.  WHO classification of tumours of the central nervous system , 2007 .

[20]  T. Merchant,et al.  Ependymoma: New Therapeutic Approaches Including Radiation and Chemotherapy , 2005, Journal of Neuro-Oncology.

[21]  A. Brandes,et al.  A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro‐Oncologia , 2005, Cancer.

[22]  R. Soffietti,et al.  Temozolomide in rare brain tumors of the adult: a prospective study , 2005 .

[23]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[24]  F. Boop.  Long-term outcome in patients harboring intracranial ependymoma. , 2005, Journal of neurosurgery.

[25]  A. Brandes,et al.  A multicenter study of the prognosis and treatment of adult brain ependymal tumors , 2004, Cancer.

[26]  D. Frappaz,et al.  Intracranial Ependymomas in Adult Patients: Analyses of Prognostic Factors , 2002, Journal of Neuro-Oncology.

[27]  D. Calvet,et al.  Response of recurrent anaplastic ependymoma to a combination of tamoxifen and isotretinoin , 2003, Neurology.

[28]  M. Wolter,et al.  Comprehensive analysis of genomic alterations in gliosarcoma and its two tissue components , 2002, Genes, chromosomes & cancer.

[29]  J. Buatti,et al.  Intracranial Ependymomas: An Analysis of Prognostic Factors and Patterns of Failure , 2002, American journal of clinical oncology.

[30]  P. Kleihues,et al.  Genetic profile of gliosarcomas. , 2000, The American journal of pathology.

[31]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.